Xlife sciences

THE LEADING EUROPEAN LIFE SCIENCES INCUBATOR AND ACCELERATOR



Disclaimer

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION WOULD BE UNLAWFUL

The presentation has been prepared by Xlife Sciences Ltd. ("Xlife", and together with its subsidiaries, the "Xlife Group") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority. The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe for or purchase any loans or securities of or make an investment in Xlife or any other member of the Xlife Group or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision.

No representation, warranty or undertaking, express or implied, is made by Xlife or any member of the Xlife Group or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained therein or any other statement made or purported to be made in connection with Xlife, the Xlife Group or any member thereof, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Xlife or any member of the Xlife Group or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Xlife's forward-looking statements prove to be incorrect, the actual results may be materially different from those Xlife expresses or implies by such statements. Xlife does not intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of their publication.

The securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended) and Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018.

COMPANY OVERVIEW

Xlife sciences

Xlife Sciences is a Swiss life sciences incubator and accelerator.

2019
LAUNCH
WITH 6 PROJECT COMPANIES

1
STOCK EXCHANGE
SPARKS SEGMENT SIX SWISS EXCHANGE SINCE FEBRUARY 2022, PREVIOUS MUNICH STOCK EXCHANGE

~5.34 M
SHARES
5.343.363 SHARES WITH A NOMINAL VALUE OF CHF 1

46.1%
FREE FLOAT
47.0% FOUNDERS, 6.9% MANAGEMENT

~180 M
MARKET CAPITALIZATION
January 2023

>40/100k
INNOVATION PARTNERS
WITH UNIVERSITIES, RESARCH INSTITUTIONS & INDUSTRY PARTNERS / ACCESS TO SCIENTISTS

25/4/35
PROJECTS COMPANIES
IN 4 INVESTMENT PILLARS WITH 35 PROJECTS

>15
EMPLOYEES
XLIFE SCIENCES AG / PROJECT COMPANIES

BUSINESS MODEL

Xlife Sciences supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

~300	~3-5	~1.5 M	~500k
INVENTION DISCLOSURES P.A.	NEW PROJECT COMPANIES P.A.	FINANCING	POTENTIAL GRANTS

WHERE WE ADD VALUE TO OUR PROJECT COMPANIES

PROOF OF CONCEPT	M&A	MARKETING
HR	STRUCTURING	BUSINESS DEVELOPMENT
RESEARCH	PATENTING	LICENSING

BREAKDOWN BY PROJECT DEVELOPMENT PHASE



EXIT STRATEGIES

- LICENSE DEAL
- TRADE SALE
- IPO

INVESTMENT PROCESS



COMPANY LEADERSHIP

MANAGEMENT

Oliver R. Baumann
Chief Executive Officer

Carl von Halem
Chief Financial Officer

Dr. Frank Plöger
Chief Scientific Officer

Christian Faber
Head of Legal & Compliance

Beat Kläui
Head of Accounting and Taxes

BOARD OF DIRECTORS

Dr. Bernhard Scholz
President of the Board of Directors

Désirée Dosch
Member of the Board of Directors

Dr. Norbert Windhab
Member of the Board of Directors

David L. Deck
Member of the Board of Directors

Mark S. Müller
Member of the Board of Directors

Simon Schöni
Member of the Board of Directors

Oliver R. Baumann
Member of the Board of Directors

ADVISORY BOARD

Prof. Dr. habil. Michael B. Klein
Politics Expert

Prof. Dr. Ernst Rietschel
Immunology Expert

Prof. Dr. Hans-Georg Rammensee
Immunology Expert

Prof. Dr. Johannes Schumacher
Human Genetics Expert

Dr. Christoph Brücher
Industry Expert

Dr. med. Uwe Rudolf Max Reuter, DM
Head Physician at Klinik Im Leben

Dr. med. Ralf Oettmeier
Head Physician at Alpstein Clinic

Dr. Bernward Garthoff
Industry Expert

Prof. Dr. Jürgen Eckel
Diabetes Expert

Prof. Dr. Ulrich Räth
Industry Expert

KEY FOCUS AREAS & PROJECT COMPANIES

Xlife sciences

TECHNOLOGY PLATFORMS

INVENTUMGENETICS

palleos healthcare

VERAXA

BIOTECH & THERAPIES

alytas therapeutics

inflamed pharma

panmabs

QUADIRABIOSCIENCES

xarma life sciences

BALIOPHARM

iX Therapeutics

Lysatpharma.

Synimmune antibodies for life

XPROT

MEDICAL TECHNOLOGY

axenoll 3D printing for life

Saniva

vitruvia WE SUSTAIN ADDED VALUES

nova xolmix

X-kidney diagnostics

clyxop devices

LAXXON MEDICAL technology for your life

X-nuclear diagnostics

Xsight Optics

NOVUM

ARTIFICIAL INTELIGENCE

FUSE-AI

XDIAGNOSTICS

SELECTED MARKETS

Xlife sciences

ONCOLOGY

- INVENTUMGENETICS
- iX Therapeutics
- QUADIRABIOSCIENCES
- XPROT
- Synimmune antibodies for life
- VERAXA
- FUSE-AI

METABOLIC / INFLAMMATION

- inflamed pharma
- Lysatpharma.
- nouaxoiiix
- BALIOPHARM
- panmabs
- xarma life sciences

MEDICAL DEVICES

- Xsight Optics
- Saniva
- vitruvia WE SUSTAIN ADDED VALUES
- clyxop devices
- NOVUM
- XDIAGNOSTICS

3D-PRINTING

- LAXXON MEDICAL technology for your life
- axenoll 3D printing for life

DIAGNOSTICS

- X-kidney diagnostic
- X-nuclear diagnostics

OBESITY

- alytas therapeutics

CRO

- palleos healthcare

PORTFOLIO

Xlife sciences

Our approach is to be in the driver seat. In over 50% of the new project companies, Xlife Sciences initiated the spin-off process directly from and with a university or research institution.

INITIAL PROJECTS #6

Lysatpharma.	25%
LAXXON MEDICAL technology for your life	5%
VERAXA	18%
Synimmune antibodies for life	37%
vitruvia WE SUSTAIN ADDED VALUES	5%
axenoll 3D printing for life	14%

SPIN-OFF #11

alytas therapeutics	51%
INVENTUMGENETICS	100%
NOVUM	67%
Xsight Optics	80%
panmabs	46%
Saniva	19%
XPROT	100%
clyxop devices	70%
xarma life sciences	46%
X-nuclear diagnostics	100%
X-kidney diagnostics	100%

STRATEGIC #5

inflamed pharma	75%
BALIOPHARM	License
palleos healthcare	50%
XDIAGNOSTICS	100%
FUSE-AI	35%

INDUSTRY JOINT VENTURE #3

QUADIRABIOSCIENCES	50%
iX Therapeutics	50%
noua xoiiix	40%

JOINT VENTURE PARTNER

abc biopply applied biomedical concepts	50%
indivumed	50%
curasan Regenerative Medicine	60%

PROJECT STAGE

Xlife sciences

TECHNOLOGY PLATFORMS

ARTIFICIAL INTELLIGENCE



BIOTECHNOLOGY & THERAPIES



MEDICAL TECHNOLOGY & DIAGNOSTICS



PRESENCE

Xlife Sciences has a recent focus on DACH. In the course of various business development activities the network has expanded into EMEA, Asia and the US.





BUSINESS PARTNERS

Xlife sciences

Xlife Sciences is build on long-term relationships and a growing network with inventors, leading universities and scientific institutions.

SYNERGIES

Xlife sciences

Xlife Sciences synergies are a key driver of success. In the Xlife family, we live synergies. Many use cases and agreements have grown genuinely between our partners.



USE CASE – VERAXA BIOTECH AG

Xlife sciences

VERAXA

Veraxa Biotech AG is a technology platform, based in Zurich and Heidelberg.
The business model is the screening and modulation of antibodies for external partners.

FUNCTIONAL ANTIBODY SCREENING
Unravelling the entire immune repertoires



ADC TECHNOLOGY
Functionalizing UAA-antibodies with click chemistry



LICENSE PARTNER

abo biopply applied biomedical concepts · YUHAN · alytas therapeutics · CHIOME · indivumed · iX Therapeutics · AXXAM INNOVATES, ENABLES, PERFORMS · MERCK

INCORPORATION	LOCATION	WEBSITE	STAKE XLIFE
2021	**Zurich, Heidelberg**	**www.veraxa.com**	**18,23%**

ESG

Xlife sciences

Our motivations is to integrate ESG in the whole group, to incorporate personal values and to make a positive impact.

DEFINE ESG-KPIs

CODE OF CONDUCT

PUBLISH ESG-REPORT

ANALYSE & IMPROVE

INTEGRATION DUE DILIGENCE

NEXT STEPS & FOCUS

Having built up the portfolio over the last few years, the main task now is to achieve successful exits with project companies, strengthen liquidity and continue to grow.

CASH EVENTS



BRAND AWARENESS



RESEARCH REPORTS

INCREASE LIQUIDITY

STRENGTHEN TEAM

VALUE INFLECTION POINTS

Xlife sciences

We intend to carry out numerous projects as a license deal, trade sale or IPO. Below potential monetization events divided in two phases from near to mid-term future.

WHY XLIFE SCIENCES

With Xlife Sciences, we enable our shareholders to invest directly in a diversified early-stage life sciences portfolio in a liquid asset.

LEAN AND COST-EFFECTIVE STRUCTURE

ACCESS TO A DIVERSIFIED PORTFOLIO

LIQUID ASSET



DISCOUNTED TRADE

PLEASE GET IN TOUCH

Xlife sciences

> Oliver R. Baumann	> Carl v. Halem	> Dennis Lennartz
CEO	CFO	Head of Investor Relations
oliver.baumann@xlifesciences.ch	carl.halem@xlifesciences.ch	dennis.lennartz@xlifesciences.ch
+41 44 385 84 60	+41 44 385 84 60	+41 44 385 84 60

where innovation leads to success

Xlife sciences



Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I Switzerland I +41 (0) 44 385 84 60 I www.xlifesciences.ch